Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov;26(6):e334-e336.
doi: 10.1111/hae.14098. Epub 2020 Aug 25.

Optimal trough levels in haemophilia B: Raising expectations

Christopher Walsh  1 , Michiel Coppens  2 , Miguel Escobar  3 , Michael Wang  4
Affiliations

Optimal trough levels in haemophilia B: Raising expectations

Christopher Walsh et al. Haemophilia. 2020 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

ME: consulting and/or member of scientific advisory committee from Takeda, Novo Nordisk, Pfizer, Kedrion, Sanofi, Genentech, FDA and National Hemophilia Foundation; MW: Consulting and member of scientific advisory committee for Takeda, Bayer, Novo Nordisk, CSL Behring, BioMarin, Genetech and Sanofi‐Bioverativ. MC: consultancy fees or research support from CSL Behring, Bayer, Novo Nordisk, UniQure, Sanquin Blood Supply, and Sobi; CEW: member of advisory board for Genentech, Takeda, and Novo Nordisk.

References

    1. Gill JC, Roberts J, Li Y, Castaman G. Sustained high trough factor IX activity levels with continued use of rIX‐FP in adult and paediatric patients with haemophilia B. Haemophilia. 2019;25(3):e219‐e222. - PMC - PubMed
    1. Shapiro A, Potts J, Li S, et al. Association of bleeding tendency with time under target FIX activity levels in severe hemophilia B patients treated with recombinant factor IX Fc fusion protein. Blood. 2013;122(21):2349.
    1. Malec L, Croteau S, Callaghan M, Sidonio R. Spontaneous bleeding and poor bleeding response with extended half‐life factor IX products: A survey of select US hemophilia treatment centers. Paper presented at: ISTH2019; Melbourne, Australia. - PubMed
    1. Kleiboer B, Nielsen B, Ma AD, Abajas Y, Monroe DM, Key NS. Excessive breakthrough bleeding in haemophilia B patients on factor IX‐albumin fusion protein prophylactic therapy: a single centre case series. Haemophilia. 2019;26(1):e13896. - PMC - PubMed
    1. Stafford DW. Extravascular FIX and coagulation. Thromb J. 2016;14(Suppl 1):35. - PMC - PubMed

Grants and funding